Centauri Therapeutics Limited
Private Limited Company · London
ActiveUnited KingdomIncorporated 2014Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-12-31
IXBRL · 170 source facts · 24 selected values
Validation findingsXBRL valid
Accounts to 2025-12-31
IXBRL · 170 source facts · 24 selected values
Validation findings
XBRL valid
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- complete
- Numeric facts
- 105
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2024-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod223_4317_08879741_20251231
- Source archive
- Accounts_Bulk_Data-2026-09-29.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2024-12-31
IXBRL · 158 source facts · 24 selected values
Validation findingsXBRL valid
Accounts to 2024-12-31
IXBRL · 158 source facts · 24 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-01-01 to 2024-12-31
- Extraction status
- complete
- Numeric facts
- 95
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2024-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2509_08879741_20241231
- Source archive
- Accounts_Monthly_Data-September2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-12-31
IXBRL · 159 source facts · 24 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 159 source facts · 24 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 96
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_1966_08879741_20231231
- Source archive
- Accounts_Monthly_Data-April2024.zip
Accounts to 2022-12-31
IXBRL · 160 source facts · 24 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 160 source facts · 24 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 97
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0015_08879741_20221231
- Source archive
- Accounts_Monthly_Data-May2023.zip
Accounts to 2021-12-31
IXBRL · 202 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2021-12-31
IXBRL · 202 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2021-01-01 to 2021-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 129
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0108_08879741_20211231
- Source archive
- Accounts_Monthly_Data-July2022.zip
Registered details
08879741- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2014-02-06
- Jurisdiction
- —
- Registered office
- FIRST FLOOR, 5 FLEET PLACE, LONDON, EC4M 7RD, UNITED KINGDOM
Classification
1 SIC codes23112
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
4 SH01-derived rounds2026-01-08
£5,999,911 raised
£38,060,192 estimated post-money
2025-02-10
£8,980,538 raised
£32,060,281 estimated post-money
2023-07-10
£8,980,538 raised
£23,079,743 estimated post-money
2022-01-26
£5,887,093 raised
£13,837,336 estimated post-money
Research and innovation
1 matched grantsOptimisation of Antibody Recruiting Molecules as ImmunotherapeuticsLead
Innovate UK · Collaborative R&D · 2017-08-01 – 2019-07-31
£945,039
awarded